SPOTLIGHT -
March 18th 2023
The company also will establish a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance.
March 14th 2023
The lower prices will take effect on Jan. 1, 2024, on both pre-filled pens and vials of basal, bolus and pre-mix insulins, including Levemir, Novolin, NovoLog and NovoLog Mix 70/30.
March 8th 2023
If approved, Jardiance would be the first SGLT2 inhibitor indicated for this population. A decision is expected in the second quarter of 2023.
March 2nd 2023
The price cuts apply to Lilly’s nonbranded insulin, Humalog, Humulin and its Lantus biosimilar.
January 23rd 2023
Once-daily, oral SGLT2 inhibitor Brenzavvy has been shown to reduce blood sugar and improve glycemic control.
FDA Accepts Jardiance sNDA for CKD Indication
A phase 3 trial showed that Jardiance reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo. An FDA decision is expected in the second half of 2023.
Study: Medicare Patients to Benefit from $35 Insulin Cap
The Inflation Reduction Act’s cap on out-of-pocket costs for insulin is likely to improve outcomes for almost half of Medicare’s insulin users.
FDA Approves Rybelsus for First-line Treatment of Diabetes
This update removes a previous limitation that it could not be used as the first therapy.
Major Diabetes Medications in Short Supply
Lilly’s first-in-class medicine that activates both the GLP-1 and GIP receptors, Mounjaro, is the latest to be included on the FDA’s drug shortages list because of high demand.
Prescryptive Health Partners with Lilly for Insulin Program
Prescryptive will offer a subscription-based program for employers that aims to provide a more predictable benefit for companies and their employees.
FDA Approves Second Interchangeable Lantus Biosimilar
Lilly’s Rezvoglar is a long-acting human insulin analog. It follows Semglee as a biosimilar that can be substituted for Lantus for both adults and children with diabetes.
FDA Approves First Drug that Delays Diabetes
Tzield addresses the underlying cause of the disease, where the immune system destroys the insulin producing cells in the pancreas. It will be available by the end of the year with a wholesale acquisition cost of $13,850 per vial.
Battery Issues Affect Omnipod Dash Personal Diabetes Managers
Omnipod DASH PDMs are at increased risk of malfunction if overcharged beyond the maximum battery voltage.
Wellcare Expands Medicare Drug Coverage, Adds Amazon as Preferred Pharmacy
A new formulary design will be offered on the Value Script and Value Plus plans; it will contain medications used to treat diabetes and will cost only $11 per 30-day supply.
FDA Expands Use of Omnipod 5 for Younger Children
Omnipod 5 is now available through retail pharmacies, as well as specialty and mail-order pharmacies.
CivicaScript Launches Generic Abiraterone
Abiraterone is used together with prednisone to treat patients with metastatic prostate cancer.
Senate Passes Bill that Caps Insulin at $35 for Medicare Beneficiaries
The Inflation Reduction Act also allows Medicare to negotiate prices on some drugs and caps out-of-pocket costs for Medicare beneficiaries.
Optum to Offer $35 Insulin to Those without Insurance
Optum has teamed up with Sanofi to provide savings cards for six insulins through the Optum Store.
FDA Extends Review of Diabetes Therapy Teplizumab
The new PDUFA date is Nov. 17, 2022. If approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes.
Sanofi Lowers Insulin Price
Sanofi has lowered the out-of-pocket cost for those without insurance of its insulins to $35 for a 30-day supply through the company’s savings program.
FDA Updates Safety Label of Byetta
Byetta is used to control blood sugar in patients with diabetes. A new warning includes the risk of gallstones and gallbladder inflammation.
Study: Medicare Part D Enrollees’ Spending for Insulin Increased
If insulin copays were capped at $35, Part D enrollees would save 29% on average, according to new analysis from Kaiser Family Foundation.
FDA Okays Lilly’s Novel Diabetes Drug
Mounjaro is a first-in-class medicine that activates both the GLP-1 and GIP receptors, which leads to improved blood sugar control.
FDA Approves Higher Dose of Ozempic
Ozempic is now available in three doses to improve blood sugar in people with type 2 diabetes.
Civica’s Allan Coukell Talks about Its Insulin Program
Allan Coukell, Civica’s senior vice president of public policy, discusses how the generic manufacturer is disrupting the market for insulins.
Civica Plans to Sell Lower-Cost Insulins
Once approved, the insulins will be available to patients for no more than $30 per vial.
Walgreens Offering Biosimilar and Interchangeable Insulin Semglee
Patients who are part of the Walgreen’s Prescription Savings Club can receive Semglee at up to 80% off the cash price.
OptumRx Excludes the Diabetes Biosimilar Semglee from Formulary
OptumRx will favor the reference product Lantus on the Premium Formulary. The organization also released coverage information about other newly approved therapies.
Biocon Launches Biosimilar Semglee
Branded and unbranded versions of the interchangeable biosimilar to treat patients with diabetes are now available.
Prime Therapeutics Adds the Biosimilar Semglee to Preferred Formulary
Prime’s formularies will include the insulin biosimilar over the reference product Lantus beginning in January 2022.
Express Scripts Adds Biosimilar Semglee to Preferred Formulary
Express Scripts will put the first interchangeable biosimilar insulin on its National Preferred Formulary and exclude Lantus, the reference product.
Lilly Lowers List Price of Insulin Lispro
Effective Jan. 1 2022, the move brings the price to 2008 levels.
FDA Approves First Interchangeable Biosimilar Insulin
The approval allows for substitution at the pharmacy counter for Lantus, its reference product.
Merck Vaccine and Other FDA Updates
Keytruda gets a full approval in endometrial cancer; while Xeljanz will miss another PDUFDA date.
FDA Panel Hearing on Roxadustat Leads the Week
FDA staff raised safety concerns ahead of the advisory panel hearing.